All In Biotech

Investigational drug · Phase 2

SYS6041

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ovarian Cancer, Recurrent Ovarian Cancer, Advanced Solid Tumors.

Phase 2

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

2

Any phase or sponsor naming "SYS6041"

First trial start

2025

Mar 28, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "SYS6041", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Ovarian Cancer
  • Recurrent Ovarian Cancer
  • Advanced Solid Tumors

Approved drugs for the same conditions: Ovarian cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "SYS6041" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Ovarian Cancer

  • SHR-A1811Trastuzumab RezetecanPhase 327 trials

    Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer

  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • GiredestrantRO7197597, GDC-9545Phase 316 trials

    Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

  • SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • FianlimabREGN3767Phase 311 trials

    Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • LBL-024Phase 311 trials

    Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma

  • R-DXdDS 6000a, MK-5909Phase 310 trials

    Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

  • SaruparibAZD5305Phase 310 trials

    AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.